PRODUCT MONOGRAPH

PrIMOVANE®
(zopiclone)

Tablets, 5.0 mg and 7.5 mg

Hypnotic and Sedative
**NAME OF DRUG**

PrIMOVANE®
(zopiclone)

Tablets, 5.0 mg and 7.5 mg

Hypnotic and Sedative

---

**WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS**

Concomitant use of zopiclone and opioids may result in profound sedation, respiratory depression, coma, and death (see WARNINGS, Risks from concomitant use of opioids and benzodiazepines or other CNS depressants).

- Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.
- Follow patients for signs and symptoms of respiratory depression and sedation.

---

**ACTIONS, CLINICAL PHARMACOLOGY**

IMOVANE (zopiclone), a cyclopyrrolone derivative, is a short-acting hypnotic agent. IMOVANE is structurally unrelated to existing hypnotics. However, the pharmacological profile of IMOVANE is similar to that of the benzodiazepines.

IMOVANE pharmacological properties are: hypnotic, sedative, anxiolytic, anti-convulsant, muscle-relaxant. These effects are related to a specific agonist action at central receptors belonging to the GABA\(_A\) macromolecular complex, modulating the opening of the chloride ion channel.

In sleep laboratory studies of one to 21-day duration in man, zopiclone reduced sleep latency, increased the duration of sleep and decreased the number of nocturnal awakenings. Zopiclone delayed the onset of REM sleep but did not reduce consistently the total duration of REM periods. The duration of stage 1 sleep was shortened, and the time spent in stage 2 sleep increased. In most studies, stage 3 and 4 sleep tended to be increased, but no change and actual decreases have also been observed. The effect of zopiclone on stage 3 and 4 sleep differs from that of the benzodiazepines, which suppress slow wave sleep. The clinical significance of this finding is not known.

With hypnotic drugs, the duration of hypnotic effect and the profile of unwanted effects may be influenced by the alpha (distribution) (t\(_{1/2\alpha}\)) and beta (elimination) (t\(_{1/2\beta}\)) half-lives of the administered drug and any active metabolites formed. When half-lives are long, the drug or
metabolite may accumulate during periods of nightly administration and be associated with impairments of cognitive and motor performance during waking hours. If half-lives are short, the drug and metabolites will be cleared before the next dose is ingested, and carry-over effects related to sedation or CNS depression should be minimal or absent. If the drug has a very short elimination half-life, it is possible that a relative deficiency (i.e., in relation to the receptor site) may occur at some point in the interval between each night’s use. This sequence of events may account for two clinical findings reported to occur after several weeks of nightly use of rapidly eliminated benzodiazepines or benzodiazepine-like hypnotics: 1) increased wakefulness during the last third of the night and 2) the appearance of increased day-time anxiety (see WARNINGS).

During nightly use and for an extended period, pharmacodynamic tolerance or adaptation to some effects of benzodiazepines or benzodiazepine-like hypnotics may develop. However in two sleep laboratory studies involving 17 patients, there was an absence of tolerance with zopiclone for treatment periods of more than 4 weeks.

Rebound insomnia:

Some manifestations of rebound insomnia have been reported both in sleep laboratory and clinical studies following the withdrawal of zopiclone (see PRECAUTIONS).

Zopiclone treatment was associated with dose-related residual effects (see PRECAUTIONS).

**Pharmacokinetics**

**Absorption:**

Zopiclone is rapidly and well absorbed. Bioavailability is more than 75%, indicating the absence of a significant first-pass effect. After the administration of 3.75 and 7.5 mg doses, peak plasma concentrations of 30 and 60 ng/mL, respectively were reached in less than 2 hours. Absorption was similar in males and females.

Repeated daily administration of a 7.5 mg oral dose for 14 days did not change the pharmacokinetic characteristics of zopiclone and did not lead to accumulation.

**Distribution:**

Zopiclone is rapidly distributed from the vascular compartment (distribution half-life \([t_{1/2}\alpha}\): 1.2 hours) while the elimination half-life is approximately 5 hours (range: 3.8 to 6.5 hours). Plasma protein binding is low (approximately 45% in the 25-100 ng/mL concentration range) and non saturable. The risk of drug interaction arising from displacement of bound drug is low. The distribution volume is 91.8-104.6 liters.
Metabolism:

Zopiclone is extensively metabolized by three major pathways; only about 4 to 5% of the drug is excreted unchanged in the urine.

An *in vitro* study indicates that cytochrome P450 (CYP) 3A4 is the major isoenzyme involved in the metabolism of zopiclone to both metabolites, and that CYP2C8 is also involved with N-desmethyl zopiclone formation.

The principal metabolites are the N-oxide derivative (~12%), which has weak pharmacological activity in animals, and the N-desmethyl metabolite (~16%), which is pharmacologically inactive.

Their apparent half-lives evaluated from the urinary data are approximately 4.5 and 7.4 hours, respectively. Both metabolites are excreted renally.

Other metabolites resulting from oxidative decarboxylation are partly eliminated via the lung as carbon dioxide. In animals, zopiclone did not induce hepatic microsomal enzymes.

Excretion:

Excretion studies, using C¹⁴-zopiclone have shown that more than 90% of the administered dose was excreted over a period of 5 days, 75% being eliminated in the urine and 16% in the feces.

The low renal clearance of unchanged zopiclone (mean 8.4 mL/min) compared with that of plasma (232 mL/min) indicates that zopiclone clearance is mainly metabolic.

Special patient population:

Elderly subjects: the absolute bioavailability of zopiclone was increased (94% vs 77% in young subjects) and the elimination half-life prolonged (~7 hours). Accumulation has not been observed on repeated dosing.

Patients with hepatic insufficiency: elimination half-life was substantially prolonged (11.9 hours) and time to peak plasma levels delayed (3.5 hours). Consequently, lower doses are recommended (see DOSAGE AND ADMINISTRATION).

In cirrhotic patients, the plasma clearance of IMOVANE is reduced by approximately 40% in relation with the decrease of the demethylation process. Therefore, dosage will have to be modified in these patients.

Patients with mild to moderate renal insufficiency: the pharmacokinetics of zopiclone were not affected. In renal insufficiency, no accumulation of zopiclone or of its metabolites has been detected after prolonged administration.
IMOVANE is removed by hemodialysis; however, hemodialysis is of no value in treating overdose due to the large volume of distribution of IMOVANE (see also SYMPTOMS AND TREATMENT OF OVERDOSAGE). Hemodialysis did not appear to increase the plasma clearance of the drug.

Lactating women: zopiclone was present in the milk, its concentration paralleled plasma levels but was about 50% lower (see PRECAUTIONS, Use in nursing mothers).

**INDICATIONS AND CLINICAL USE**

_Sleep disturbance may be the presenting manifestation of a physical and/or psychiatric disorder. Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the patient has been carefully evaluated._

IMOVANE (zopiclone) is indicated for the short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings.

Treatment with IMOVANE should usually not exceed 7-10 consecutive days. Use for more than 2-3 consecutive weeks requires complete re-evaluation of the patient. Prescriptions for IMOVANE should be written for short-term use (7-10 days) and it should not be prescribed in quantities exceeding a 1-month supply.

The use of hypnotics should be restricted for insomnia where disturbed sleep results in impaired daytime functioning.

**CONTRAINDICATIONS**

IMOVANE is contraindicated in patients with:
- known hypersensitivity to the drug or to any component in its formulation. For a complete listing, see PHARMACEUTICAL INFORMATION, Composition section.
- myasthenia gravis
- severe hepatic insufficiency
- severe impairment of respiratory function (e.g., significant sleep apnea syndrome).

**WARNINGS**

General:

Benzodiazepine and benzodiazepine-like compounds should be used with extreme caution in patients with a history of substance or alcohol abuse.
Because some of the adverse effects of IMOVANE may be dose related, the smallest possible effective dose should be prescribed, especially for elderly patients. Inappropriate, heavy sedation in the elderly may result in accidental events/falls. The use of the lowest effective dose is also consistent with management of other dose-related risks associated with zopiclone (see below: Amnesia, Complex sleep-related behaviours, CNS Depressant Effects and Next-Day Impairment, Drug abuse, dependence and withdrawal).

The cause of insomnia should be identified wherever possible and the underlying factors treated before a hypnotic is prescribed. The failure of insomnia to remit after 7-10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness or the presence of sleep state misperception.

Worsening of insomnia or the emergence of new abnormalities of thinking or behaviour may be the consequence of an unrecognized psychiatric or physical disorder. These have also been reported to occur in association with the use of drugs that act at the benzodiazepine receptors.

IMOVANE should be used with caution in patients who in the past manifested paradoxical reactions to alcohol and/or sedative medications.

Lactose is a non-medicinal ingredient in IMOVANE 5 mg. Patients with rare hereditary diseases of galactose intolerance (galactosemia or glucose-galactose malabsorption) should not take IMOVANE 5 mg. IMOVANE 7.5 mg does not contain lactose.

Pregnancy:

The use of IMOVANE during pregnancy is not recommended.

If IMOVANE is prescribed to a woman of child-bearing potential, the patient should be warned of the potential risk to a fetus and advised to consult her physician regarding the discontinuation of the drug if she intends to become pregnant or suspects that she is pregnant.

Zopiclone crosses the placenta.

Benzodiazepines may cause fetal damage when administered during pregnancy. During the first trimester of pregnancy, several studies have suggested an increased risk of congenital malformations associated with the use of benzodiazepines. In certain epidemiological case-control studies, an increased incidence of cleft lip and palate was observed with benzodiazepines.

During the last weeks of pregnancy or during labor, ingestion of therapeutic doses of benzodiazepine hypnotic drugs has resulted in neonatal CNS depression due to transplacental distribution. Similar effects can be expected to occur with zopiclone, due to its pharmacological effects. Cases of reduced fetal movement and fetal heart rate variability have been described after administration of benzodiazepines during the second and/or third trimester of pregnancy.
Administration of IMOVANE during the late phase of pregnancy or during labor has been associated with effects on the neonate, such as hypothermia, hypotonia, feeding difficulties (which may result in poor weight gain) and respiratory depression.

A child born to a mother who took sedative/hypnotics agents chronically during the latter stages of pregnancy may have developed physical dependence and may be at risk for developing withdrawal symptoms in the postnatal period. Appropriate monitoring of the newborn in the postnatal period is recommended.

Amnesia:

Anterograde amnesia of varying severity has been reported following therapeutic doses of benzodiazepines or benzodiazepine-like agents. The event is rare with IMOVANE. Anterograde amnesia may occur, especially when sleep is interrupted or when retiring to bed is delayed after the intake of the tablet. Anterograde amnesia is a dose-related phenomenon and elderly subjects may be at particular risk.

Cases of transient global amnesia and “traveler’s amnesia” have also been reported in association with benzodiazepines, the latter in individuals who have taken the drug, often in the middle of the night, to induce sleep while travelling. Transient global amnesia and traveler’s amnesia are unpredictable and not necessarily dose-related phenomena.

To reduce the possibility of anterograde amnesia, patients should ensure that they take the tablet strictly when retiring for the night. Patients should be warned not to take IMOVANE under circumstances in which a full night’s sleep and clearance of the drug from the body are not possible before they need again to resume full activity.

Abnormal thinking and behavioural changes:

Abnormal thinking and other behavioural changes have been reported to occur in association with the use of benzodiazepines and benzodiazepine-like agents including IMOVANE, although rarely (see ADVERSE REACTIONS). Some of the changes may be characterized by decreased inhibition, e.g., aggression or extroversion that seems excessive, similar to that seen with alcohol and other CNS depressants (e.g., sedative/hypnotics). Particular caution is warranted in patients with a history of violent behaviour and a history of unusual reactions to sedatives including alcohol and the benzodiazepines or benzodiazepine-like agents. Psychotic behavioural changes that have been reported include abnormal behaviour, restlessness, agitation, irritability, hallucinations, delusion, anger, nightmare and depersonalization. Abnormal behaviours associated with the use of benzodiazepines or benzodiazepine-like agents have been reported more with chronic use and/or high doses but they may occur during the acute, maintenance or withdrawal phases of treatment.

It can rarely be determined with certainty whether a particular instance of abnormal behaviours listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric disorder. Nevertheless, the emergence of any new behavioural sign or symptom of concern
requires careful and immediate evaluation. Should these occur, use of the product should be discontinued. These reactions are more likely to occur in the elderly.

**Cognitive Function:**

The benzodiazepines and benzodiazepine-like agents affect mental efficiency, e.g., concentration, attention and vigilance. The risk of confusion is greater in the elderly and in patients with cerebral impairment.

**Anxiety, restlessness:**

An increase in daytime anxiety and/or restlessness has been observed during treatment with IMOVANE. This may be a manifestation of interdose withdrawal, due to the short elimination half-life of the drug.

**Depression:**

Caution should be exercised if IMOVANE is prescribed to patients with signs and symptoms of depression that could be intensified by hypnotic drugs. The potential for self-harm (e.g., intentional overdose) is high in patients with depression and thus, the least amount of drug that is feasible should be available to them at any one time.

As with other hypnotics, IMOVANE does not constitute a treatment of depression and may even mask its symptoms (see PRECAUTIONS).

**Complex sleep-related behaviours:**

Complex sleep-related behaviours such as “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported in patients who have taken IMOVANE. Other potentially dangerous behaviours have been reported in patients who got out of bed after taking a sedative-hypnotic and were not fully awake, including preparing and eating food, making phone calls, leaving the house, etc. As with “sleep-driving”, patients usually do not remember these events. Although complex sleep-related behaviours may occur with IMOVANE alone at therapeutic doses, the use of alcohol and other CNS-depressants with IMOVANE appears to increase the risk of such behaviours, as does the use of IMOVANE at doses exceeding the maximum recommended dose.

**IMOVANE is not to be taken with alcohol.**

Caution is needed with concomitant use of other CNS depressants drugs.

Caution is recommended in patients with a personal or family history of sleepwalking. Although complex sleep-related behaviours have been reported in patients with or without history of sleepwalking, it is possible that some predisposed patients are at increased risk of experiencing these complex behaviours during treatment with IMOVANE.
The use of IMOVANE in patients with other disorders known to affect sleep and induce frequent awakenings (e.g. sleep apnea, Periodic Limb Movement Disorder, Restless Legs Syndrome) is discouraged, as they may be also at increased risk of complex sleep-related behaviours.

Treatment with IMOVANE is limited to a short duration (see INDICATIONS, DOSAGE AND ADMINISTRATION).

Patients should be instructed not to exceed the recommended dose.

Caution should be exercised with concomitant use of potent CYP3A4 inhibitors (see DRUG INTERACTIONS).

Due to the risk to the patient and the community, discontinuation of IMOVANE should be strongly considered for patients who report any such complex sleep-related behaviours.

CNS Depressant Effects and Next-Day Impairment

Like other sedative/hypnotic drugs, IMOVANE has CNS-depressant effects. Due to the rapid onset of action, IMOVANE should be ingested immediately prior to going to bed.

Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug.

This includes potential impairment of the performance of such activities that may occur the day following ingestion of IMOVANE. The risk of next day psychomotor impairment, including impaired driving, is increased if IMOVANE is taken with less than a full night of sleep remaining; if a higher dose than the recommended dose is taken; if co-administered with other CNS depressants or drugs that increase the blood level of zopiclone. Patients should be cautioned against taking IMOVANE in these circumstances.

The lowest effective dose for the patient should be used.

IMOVANE is not to be taken with alcohol or other sedative hypnotics (including other zopiclone products) at bedtime or the middle of the night. If concomitant use of another CNS depressant or a drug that increases zopiclone blood levels is clinically warranted, dosage adjustments of IMOVANE may be necessary.

Even if IMOVANE is taken as instructed, some patients may still have zopiclone blood levels in the morning high enough to produce impairment (see DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS).

Patient counseling information regarding next-day impairment: Tell patients that IMOVANE has the potential to cause next-day impairment, and that this risk is increased if dosing instructions
are not carefully followed. Tell patients not to drive a car or engage in hazardous activities requiring complete alertness until they experience how the drug affects them the next day. Tell patients that if they took IMOVANE as instructed and do not feel drowsy in the morning, they still have to wait for at least 12 hours after dosing before driving or engaging in other activities requiring full mental alertness, especially for elderly patients and for patients who take the 7.5 mg dose. Inform patients that impairment can be present despite feeling fully awake.

Risks from concomitant use of opioids and benzodiazepines or other CNS depressants:
Concurrent use of IMOVANE with opioids, benzodiazepines, or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics.

If a decision is made to prescribe IMOVANE concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of IMOVANE than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking IMOVANE, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression and sedation (see DRUG INTERACTIONS).

Advise both patients and caregivers about the risks of respiratory depression and sedation when IMOVANE is used with opioids.

Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the opioid have been determined (see Serious Warning and Precautions box, and WARNINGS, CNS Depressant Effects and Next-Day Impairment).

Severe Anaphylactic and Anaphylactoid Reactions:

Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including IMOVANE. Some patients have had additional symptoms such as dyspnea, throat closing or nausea and vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the throat, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with IMOVANE should not be rechallenged with the drug.
Drug abuse, dependence and withdrawal:

Use of IMOVANE may lead to the development of abuse and/or physical and psychological dependence. The risk of dependence increases with the dose and duration of treatment. Cases of dependence have been reported more frequently in patients treated with IMOVANE for longer than 4 weeks. The risk of abuse and dependence is also greater in patients with a history of psychiatric disorders and/or alcohol or drug abuse. IMOVANE should be used with extreme caution in patients with current or a history of alcohol or drug abuse. Interdose daytime anxiety and rebound anxiety may increase the risk of dependency in IMOVANE treated patients.

Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms.

Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting, sweating, dysphoria, perceptual disturbances and insomnia) have occurred following abrupt discontinuation of benzodiazepines and benzodiazepine-like agents, including IMOVANE. The more severe symptoms are usually associated with higher dosages and longer usage, although patients given therapeutic dosages for as few as 1-2 weeks can also have withdrawal symptoms including daytime anxiety between nightly doses.

Consequently, abrupt discontinuation should be avoided and a gradual dosage tapering schedule is recommended in any patient taking the drug for more than a few weeks. The recommendation for tapering is particularly important in patients with a history of seizures (see ADVERSE REACTIONS, Withdrawal Symptoms).

As with all hypnotics, repeat prescriptions should be limited to those who are under medical supervision.

It may be useful to inform the patient when treatment is started that it will be of limited duration and to explain precisely how the dosage will be progressively decreased.

Rebound insomnia

A transient syndrome, whereby the symptoms that led to treatment with a sedative/hypnotic agent may recur in an enhanced form, upon treatment withdrawal. It may be accompanied by other reactions, including mood changes, anxiety and restlessness.

Since the risk of such phenomena is greater after abrupt discontinuation of IMOVANE, especially after prolonged treatment, it is, therefore recommended to decrease the dosage gradually and to advise the patient accordingly (see ADVERSE REACTIONS). It is important that the patient should be aware of the possibility of rebound phenomena, thereby minimizing anxiety over such symptoms should they occur while the medicinal product is being discontinued.
Suicidality and Depression

Several epidemiological studies show an increased incidence of suicide and suicide attempt in patients with or without depression, treated with benzodiazepines and other hypnotics, including zopiclone. A causal relationship has not been established.

As with other sedative-hypnotic drugs, IMOVANE should be administered with caution in patients exhibiting symptoms of depression. Suicidal tendencies may be present, therefore the lowest possible quantity of IMOVANE should be supplied to these patients to reduce the risk of intentional overdosage by the patient. Since insomnia may be a symptom of depression, the patient should be re-evaluated if insomnia persists. In these patients, more direct monitoring of suicidal thinking may be warranted.

Tolerance

Some loss of efficacy of other hypnotics may develop after repeated use. However, there was an absence of tolerance with IMOVANE for treatment periods of up to 4 weeks.

Patients with specific conditions:

IMOVANE should be given with caution to patients with impaired hepatic or renal function, or chronic pulmonary insufficiency. Dosage adjustments are recommended (see DOSAGE AND ADMINISTRATION). Respiratory depression has been reported in patients with compromised respiratory function. As hypnotics have the capacity to depress respiratory drive, precautions should be observed if IMOVANE is prescribed to patients with compromised respiratory function.

IMOVANE is contraindicated in patients with myasthenia gravis and severe hepatic insufficiency and in those with severe impairment of respiratory function, e.g., significant sleep apnea syndrome (see CONTRAINDICATIONS).

Use in pregnancy:

The use of IMOVANE during pregnancy is not recommended (see WARNINGS section).

Use in nursing mothers:

IMOVANE is excreted in human milk, and its concentration may reach 50% of the plasma levels. Insufficient data are available on IMOVANE to assess its safety during lactation. Therefore, the administration of IMOVANE to nursing mothers is not recommended.

Pediatrics (< 18 years of age):

The safety and effectiveness of IMOVANE in children and young adults below the age of 18 have not been established. IMOVANE should not be prescribed in pediatric patients.
Geriatrics (≥ 65 years of age):

Elderly patients are especially susceptible to dose-related adverse effects, such as drowsiness, dizziness, or impaired coordination. Inappropriate, heavy sedation may result in accidental events/fall. Therefore, the IMOVANE dose in elderly patients should not exceed 5 mg (see DOSAGE AND ADMINISTRATION, Geriatric patients). Anterograde amnesia is a dose-related phenomenon and elderly subjects may be at particular risk.

**DRUG INTERACTIONS**

The risk of drug interaction arising from displacement of bound drug is low.

**Alcohol**
Concomitant intake with alcohol is not recommended (see WARNINGS, Complex sleep-related behaviours). IMOVANE may produce additive CNS depressant effects when co-administered with alcohol.

**CNS Depressants**
IMOVANE may produce additive CNS depressant effects when co-administered with sedative antihistamines, anticonvulsants, narcotic analgesics, anesthetics, or psychotropic medications such as antipsychotics (neuroleptics), hypnotics, anxiolytics/sedatives, and antidepressant agents which themselves can produce CNS depression. In the case of narcotic analgesics, enhancement of euphoria may also occur, leading to an increase in psychological dependence.

**Drugs Affecting Cytochrome P450 Enzymes**
Since IMOVANE is metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Metabolism), plasma levels of IMOVANE may be increased when co-administered with CYP3A4 inhibitors, such as erythromycin, clarithromycin, ketoconazole, itraconazole, and ritonavir. A dose reduction for IMOVANE may be required when it is co-administered with CYP3A4 inhibitors. Conversely, plasma levels of IMOVANE may be decreased when co-administered with CYP3A4 inducers, such as rifampicin or rifampin, carbamazepine, phenobarbital, phenytoin, and St. John’s wort. A dose increase for IMOVANE may be required when it is co-administered with CYP3A4 inducers (see WARNINGS).

The effect of erythromycin on the pharmacokinetics of IMOVANE has been studied in 10 healthy subjects. The AUC of IMOVANE is increased by 80% in presence of erythromycin, a possible consequence of erythromycin inhibition of IMOVANE metabolism by CYP3A4. As a consequence, the hypnotic effect of IMOVANE may be enhanced when administered with erythromycin or other CYP3A4 inhibitors.

**Opioids**
Due to additive CNS depressant effect, the concomitant use of benzodiazepines or other CNS
depressants, including IMOVANE, and opioids increases the risk of profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations of concomitant use of benzodiazepines and opioids to the minimum required. Follow patients closely for respiratory depression and sedation (see Serious Warning and Precautions box, and WARNINGS, Risks from concomitant use of opioids and benzodiazepines or other CNS depressants).

ADVERSE REACTIONS

The most common adverse reaction seen with IMOVANE is taste alteration (bitter taste). Severe drowsiness and/or impaired coordination are signs of drug intolerance or excessive doses.

The following adverse events were observed in patients receiving IMOVANE. In the absence of an established cause-effect relationship those adverse reactions that were observed more frequently with IMOVANE than with a placebo are in italic.

Central Nervous System: *Somnolence, dizziness, confusion, anterograde amnesia or memory impairment, feeling of drunkenness, euphoria, nightmares, agitation, anxiety or nervousness, hostility, depression, decreased libido, libido disorder, coordination abnormality, headache, hypotonia, tremor, muscle spasms, paresthesia, and speech disorder.*

Hallucinations, aggression, irritability and fall (predominantly in elderly patients).

Cardiovascular: palpitations

Digestive: *dysgeusia (bitter taste), dry mouth, coated tongue, bad breath, nausea, vomiting, diarrhea, constipation, anorexia or increased appetite*

General Disorders and Administration Site Conditions: asthenia, chills, fatigue

Respiratory: dyspnea

Special senses: amblyopia

Dermatologic: rash, spots on skin, sweating, pruritus. Rashes and pruritus may be a sign of drug hypersensitivity; discontinue if this occurs. Angioedema and/or anaphylactic reactions have been reported very rarely.

Metabolic and nutritional: weight loss

Musculoskeletal: limb heaviness
Laboratory tests: There have been sporadic reports of abnormal laboratory test values. Mild to moderate increases in serum transaminase and/or blood alkaline phosphatase have been reported very rarely.

Geriatric patients: Geriatric patients tended to have a higher incidence of palpitations, vomiting, anorexia, sialorrhea, confusion, agitation, anxiety, tremor and sweating than younger patients. Anterograde amnesia is a dose-related phenomenon and elderly subjects may be at particular risk.

Withdrawal symptoms: Withdrawal syndrome has been reported upon discontinuation of IMOVANE (see PRECAUTIONS, Drug abuse, dependence and withdrawal). Withdrawal symptoms vary and may include rebound insomnia, muscle pain, anxiety, tremor, sweating, agitation, confusion, headache, palpitations, tachycardia, delirium, nightmares, irritability. In severe cases the following symptoms may occur: derealisation, depersonalisation, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact, hallucinations. In very rare cases, seizures may occur.

Postmarket Experience:

Psychiatric disorders: restlessness, delusion, anger, abnormal behaviours (possibly associated with amnesia) and somnambulism (see WARNINGS, Complex sleep-related behaviours), withdrawal syndrome and dependence have been reported rarely.

Respiratory: respiratory depression

Nervous system disorder: ataxia, paresthesia (not associated with withdrawal), disturbance in attention

Eye disorder: diplopia

Gastrointestinal disorders: dyspepsia

Musculoskeletal and connective tissue disorders: muscular weakness.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Signs and Symptoms:

Overdose is usually manifested by varying degrees of central nervous system depression ranging from drowsiness to coma according to the quantity ingested. In mild cases, symptoms include drowsiness, confusion, and lethargy; in more severe cases, symptoms may include ataxia, hypotonia, hypotension, methaemoglobinaemia, respiratory depression, and coma. Overdose should not be life threatening unless combined with other CNS depressants, including alcohol.
Other risk factors, such as the presence of concomitant illness and the debilitated state of the patient, may contribute to the severity of symptoms and very rarely can result in fatal outcome.

In voluntary or accidental cases of IMOVANE overdosage involving doses up to 340 mg, the principal effects reported were prolonged sleep, drowsiness, lethargy and ataxia.

**Recommended Treatment:**

Symptomatic and supportive treatment in adequate clinical environment is recommended, attention should be paid to respiratory and cardiovascular functions. Gastric lavage or activated charcoal is only useful when performed soon after ingestion.

Hemodialysis is of no value due to the large volume of distribution of IMOVANE. Flumazenil may be a useful antidote; however, flumazenil administration may contribute to the appearance of neurological symptoms (agitation, anxiety, convulsions and emotional lability). Intravenous fluids should be administered as needed.

**Poison Control Center:**

As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

**DOSAGE AND ADMINISTRATION**

Use the lowest effective dose of IMOVANE for the patient. IMOVANE should be taken in a single intake and not be re-administered during the same night.

As with all hypnotics, long-term use of zopiclone is not recommended. Treatment with IMOVANE should usually not exceed 7-10 consecutive days. Use for more than 2-3 consecutive weeks requires complete re-evaluation of the patient, since the risk of abuse and dependence increases with the duration of treatment (see PRECAUTIONS).

The product should be taken just before retiring for the night.

**Adult dose:** The recommended initial dose is 3.75 mg (one-half of a 7.5 mg tablet). The dose can be increased to 5 mg and further to 7.5 mg if clinically indicated. In some patients, the higher doses result in zopiclone blood levels in the morning high enough to produce impairment of driving and other activities that require full alertness (see WARNINGS, CNS Depressant Effects and Next-Day Impairment).

The 7.5 mg dose should not be exceeded (see WARNINGS and PRECAUTIONS).
Geriatrics (≥ 65 years of age): In the elderly and/or debilitated patient an initial dose of 3.75 mg (one-half of a 7.5 mg tablet) at bedtime is recommended. The dose may be increased to a maximum of 5 mg if the starting dose does not offer adequate therapeutic effect.

Patients with impaired liver function: The recommended dose is 3.75 mg (one-half of a 7.5 mg tablet) depending on acceptability and efficacy. If clinically indicated, a 5 mg may be used with caution in appropriate cases.

IMOVANE is contraindicated in patients with severe hepatic insufficiency (see CONTRAINDICATIONS).

Patients with renal insufficiency: Although no accumulation of IMOVANE or of its metabolites has been detected in cases of renal insufficiency, it is recommended that patients with impaired renal function should start treatment with 3.75 mg (one-half of a 7.5 mg tablet). If clinically indicated, a 5 mg may be used with caution in appropriate cases.

Patients with chronic respiratory insufficiency: The recommended dose is 3.75 mg (one-half of a 7.5 mg tablet) depending on acceptability and efficacy. Up to 7.5 mg may be used with caution in appropriate cases.

IMOVANE is contraindicated in patients with severe impairment of respiratory function, e.g., significant sleep apnea syndrome (see CONTRAINDICATIONS).

Use with potent CYP3A4 inhibitors: An initial dose of 3.75 mg (one-half of a 7.5 mg tablet) at bedtime is recommended (see DRUG INTERACTIONS). If clinically indicated, 5 mg may be used with caution in appropriate cases.

Use with CNS depressants: Dosage adjustment may be necessary when IMOVANE is combined with other CNS-depressants because of the potentially additive effects (see DRUG INTERACTIONS).

Pediatrics (< 18 years of age): IMOVANE is not indicated for patients under 18 years of age.
PHARMACEUTICAL INFORMATION

(i) Drug substance:

Proper Name: Zopiclone
Chemical Name: (5RS)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate

Structural formula:

![Structural formula image]

Molecular formula: C_{17}H_{17}ClN_{6}O_{3}
Molecular weight: 388.8
Description: A white or slightly yellowish powder, practically insoluble in water, freely soluble in methylene chloride, sparingly soluble in acetone, practically insoluble in alcohol. It dissolves in dilute mineral acids. It melts at about 177 °C, with decomposition.

(ii) Composition:

Zopiclone 7.5 mg: Non-medicinal ingredients core: croscarmellose sodium, calcium phosphate dihydrate dibasic, magnesium stearate, microcrystalline cellulose.

Non-medicinal ingredients coating: carnauba wax, FD&C Blue #1, Opadry II White, polyethylene glycol.
Zopiclone 5.0 mg: Non-medicinal ingredients core: corn starch, dicalcium phosphate, lactose, magnesium stearate, sodium carboxymethyl starch.

Non-medicinal ingredients coating: hydroxypropyl-methylcellulose, titanium dioxide

(iii) Storage recommendations:

Store in a dry place, at room temperature (15° - 30°C). Protect from light.

Keep in a safe place out of reach of children.

AVAILABILITY OF DOSAGE FORMS

Zopiclone 7.5 mg:
Each oval, scored, blue tablet, marked IMOVANE on one side and the logo rPr on each side of the score on the other side, contains zopiclone 7.5 mg. The 7.5 mg tablet can be broken into two equal parts of 3.75 mg.

Available in white high-density polyethylene bottles of 100 and 500.

Zopiclone 5.0 mg:
Each round, white tablet, marked IMOVANE 5 on one side and the logo rPr on the other, contains zopiclone 5.0 mg.

Available in white high-density polyethylene bottles of 100.

PHARMACOLOGY

Zopiclone, a cyclopyrrolone derivative, is a chemically novel hypnotic agent. However, the pharmacological and behavioural evaluation of the drug has shown that its effects are similar to those of the benzodiazepines.

1. CNS Activity

Zopiclone antagonizes chemically and electroshock-induced seizures in mice and rats. While it potently affects convulsive conditions that involve GABA, it is relatively ineffective when glycine, another inhibitory amino acid, is involved.
Zopiclone exerts muscle relaxant activity; it inhibits the traction grasping reflex in mice, reduces the ability of mice and rats to remain on a rotarod and inclined screen, respectively, relaxes the hind legs of normal cats and blocks polysynaptic reflexes in chloralosed cats.

Zopiclone also exerts antiaggressive activity; it inhibits footshock-induced fighting behaviour in mice and septal lesion-induced aggression in rats.

In a “conflict” situation, the drug increases punishment-suppressed lever-pressing behaviour, which is indicative of anxiolytic activity. Non-punished responding, indicative of non-specific sedation, is suppressed only at higher doses.

While zopiclone does not cause loss of righting reflex in normal mice, it potentiates narcosis induced by hexobarbital or ethanol.

In a drug discrimination paradigm, where rats are trained to discriminate drug from saline, the zopiclone discriminative stimulus generalized to several benzodiazepines as well as to pentobarbital. The finding that the benzodiazepines and a barbiturate were able to substitute for zopiclone indicates that zopiclone belongs to the same class of drugs.

Tolerance does not develop to the behavioural effects of zopiclone, since the anticonvulsant and taming ED50's are similar in naive and zopiclone-treated animals.

2. Receptor binding studies

Zopiclone has a high and specific affinity for benzodiazepine binding sites in several rat brain regions. The drug can inhibit the binding of 3H-benzodiazepines, but can itself label the sites that are recognized both by benzodiazepine agonists and Ro 15-1788, a benzodiazepine antagonist. Zopiclone does not recognize the peripheral benzodiazepine receptor sites and lacks affinity for the serotonin, GABA, α1 and α2 adrenergic, and dopamine receptors.

The interaction of zopiclone with the benzodiazepine receptor/GABA receptor/chloride channel complex differs somewhat from that of the benzodiazepines; while it decreases cGMP concentration in rat cerebellum, its binding is not enhanced either by GABA or by the chloride anion.

3. Dependence Liability

In barbital-dependent rhesus monkeys, zopiclone suppressed the abstinence symptoms which appeared upon withdrawal. Partial and complete suppression was observed at 4 and 16 mg/kg doses, respectively.

Zopiclone, when administered to monkeys at a dose of 16 mg/kg/day for 28 days, precipitated withdrawal signs of moderate severity. Peak symptoms appeared three and
four days after withdrawal and included hyperirritability, restlessness, tremor, and some weight loss. The administration of a higher dose for two weeks brought about similar symptoms upon withdrawal without precipitating convulsions.

Zopiclone was self-administered both intravenously and intragastrically in monkeys. When the drug was changed to saline, the rate of self-administration declined rapidly.

4. Cardiovascular and Respiratory Effects

Zopiclone was evaluated in conscious and anesthetized cats, dogs, rabbits and monkeys with regard to its effect on respiration and several cardiovascular parameters. Most of the studies involved i.v. administration.

In general, respiration and blood pressure decreased in a dose-dependent fashion while heart rate and EKG showed little change. Zopiclone affected central respiratory control mechanisms to a greater extent than the cardiovascular regulatory mechanisms.

5. Drug-Interaction Studies

Zopiclone was evaluated in combination with several drugs and in general interacted either in an additive or synergistic fashion with diazepam, phenobarbital, trimethadione, chlorpromazine, hexobarbital, and ethanol. Zopiclone did not modify the effects of phenytoin, morphine, ketoprofen and gallamine.

The effects of zopiclone could be reversed by Ro 15-1788 (flumazenil) a specific benzodiazepine antagonist.

**TOXICOLOGY**

ACEUTE TOXICITY

Studies were carried out in both sexes of several species. The results are summarized in the Table.

<table>
<thead>
<tr>
<th>SPECIES</th>
<th>ROUTE</th>
<th>LD50 (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mice</td>
<td>i.v.</td>
<td>450</td>
</tr>
<tr>
<td></td>
<td>i.p.</td>
<td>580</td>
</tr>
<tr>
<td></td>
<td>p.o.</td>
<td>1150</td>
</tr>
<tr>
<td>Rats</td>
<td>p.o.</td>
<td>2300</td>
</tr>
<tr>
<td>Dogs</td>
<td>p.o.</td>
<td>≥ 4500</td>
</tr>
<tr>
<td></td>
<td>i.v.</td>
<td>~ 400</td>
</tr>
<tr>
<td>Cats</td>
<td>p.o.</td>
<td>&gt; 1500</td>
</tr>
<tr>
<td>Rabbits</td>
<td>p.o.</td>
<td>~ 2500</td>
</tr>
<tr>
<td>Monkeys</td>
<td>p.o.</td>
<td>&gt; 4500</td>
</tr>
</tbody>
</table>
Symptoms of toxicity included sedation, CNS depression, ataxia, respiratory depression, and dyspnea. In dogs, the i.v. administration of zopiclone was followed by myoclonic seizures.

LONG-TERM TOXICITY STUDIES

1. Rats (CD Strain)

   One-month oral study
   Ten rats/sex/dose received zopiclone by gavage six days per week at doses of 0, 6, 24 and 120 mg/kg. Dose-related sedation and paresis of hind legs were observed.

   Thyroid weights were increased in male rats at all dose levels. In the high dose males, heart and spleen weights were reduced.

   Three-month oral study
   Fifteen rats/sex/dose received zopiclone by gavage seven days per week at doses of 0, 2, 12 and 120 mg/kg. At the mid and high doses, dose-related hypotonia, adynamia and ptosis were observed, all of which subsided with time. Weight gain was slightly but significantly less in mid and high dose male rats than in controls.

   At the 120 mg/kg dose the following changes occurred. BSP values decreased in both sexes; the number of RBC decreased in females; liver weights increased in both males and females, accompanied by slight changes in the parenchymal liver cells, namely eosinophilia or basophilia in the portal area.

   18-month oral study
   Fifty rats/sex/dose received zopiclone in the diet at doses of 0, 2, 20 and 200 mg/kg. Of these animals 15 rats/sex/dose were sacrificed at six months. The lowest dose was well tolerated.

   At the high dose the following changes were seen: weight gain was reduced by about 30% in both sexes; plasma protein levels were elevated at 3 and 6 months in the males and throughout the study in the females; albumin and globulin levels were elevated; thyroid weights were increased in male rats, accompanied by thyroid hyperplasia and, in some rats, by follicular adenomas; liver weights were increased in female rats both at 6 and 18 months; hepatocellular hypertrophy occurred in both sexes.

2. Dogs (Beagle)

   One-month oral study
   One dog/sex/dose received zopiclone six days per week at doses of 0, 6, 24 and 120 mg/kg. Dose-related sedation and hypotonia of the hind legs were observed. High dose dogs and the intermediate dose female dog exhibited moderate weight loss.
At the high dose, both dogs had Heinz bodies in circulating erythrocytes and the bone marrow showed erythroblastic hyperplasia. In addition, the male animal had marked anemia and active erythropoiesis in the spleen. BUN values were increased at all doses in a dose-related fashion; liver function tests were somewhat elevated.

**Six-month oral study**
Six dogs/sex/dose received zopiclone seven days per week at doses of 0, 5, 10 and 25 mg/kg. One dog/sex from each group was sacrificed after a 3-month recovery period. Zopiclone caused slight excitation, ataxia and drowsiness, and drowsiness and sleep at the 5, 10, and 25 mg/kg doses respectively. Late in the study, four dogs had epileptoid seizures and three of them died. A reduced weight gain was observed only in high dose male dogs.

Platelet counts rose substantially above normal in two high dose female dogs. Transaminase levels were elevated but not in a dose-dependent manner. Alkaline phosphatase levels were significantly elevated both in male and female dogs, receiving the 25 mg/kg dose.

While liver weights increased both in male and female dogs in a dose-dependent fashion, they returned toward control values following the 3-month recovery period. In high dose male animals, relative spleen, kidney and adrenal weights were significantly increased. Examination of bone marrow smears showed that the proportion of proerythroblasts and the ratio of normoblasts to basophilic erythroblasts were significantly greater in high dose females than in controls.

**One-year oral study**
Five dogs/sex/dose received zopiclone seven days per week at doses of 0, 1, 5 and 25 mg/kg. Zopiclone induced ataxia, sleepiness, lethargy, decreased activity, body tremors and excitability. The latter two effects occurred prior to dosing, while the others were seen shortly after dosing. After six months of treatment, zopiclone induced epileptoid seizures in five dogs (four high dose, one mid dose). Since the convulsions were observed early morning prior to dosing, they might have been a manifestation of withdrawal. Female dogs, treated with 5 mg/kg of zopiclone, were significantly heavier than controls. Treated animals both ate and drank more than did their respective controls.

Platelet counts were elevated in both sexes at the 5 and 25 mg/kg doses. Alkaline phosphatase was elevated from the first month on in mid and high dose animals. T4 values in high dose males and BSP values in high dose females were also elevated.

There was a dose-dependent increase in liver weights which became statistically significant at the 25 mg/kg dose. The elevated liver weights were associated with histopathological changes, namely vacuolation of hepatocyte cytoplasm with eosinophilic hyaline bodies.
CARCINOGENICITY

Oncogenicity studies were carried out with zopiclone in rats and mice with doses of 1, 10, 100 mg/kg/day for two years. There was an increased incidence of mammary tumours with a shift toward more anaplastic forms in female and an increase of thyroid tumours in male rats on the high dose. In the mouse study, females on the high dose had an increased incidence of pulmonary adenocarcinomas; while males on the high dose had a high number of subcutaneous soft tissue tumours.

In a wide battery of tests, it was shown that zopiclone has no mutagenic or clastogenic (chromosome-damaging) properties; urine extracts from zopiclone treated mice, rats and humans were similarly not mutagenic.

The effect of zopiclone is that of a non-genotoxic oncogen; tumor redistribution phenomena are frequently observed in rodent carcinogenicity studies, particularly with drugs acting on the central nervous system and the hormonal balance. The rise of 17 beta-estradiol may be regarded as a cause for the emergence of mammary tumours and the shift from well differentiated to poorly differentiated mammary carcinomas. The altered feedback mechanism following accelerated clearance of T4 and the rise of TSH is responsible for thyroid overstimulation that leads to formation of thyroid neoplasms. The soft tissue tumours of male mice are brought about by fighting (a paradoxical reaction) and subsequent initiation by encrustation and foreign body reaction. The increased incidence of pulmonary adenocarcinomas in female mice may be regarded as fortuitous (“chance finding”), but there is not enough data available to exclude some other mechanisms.

No comparable endocrine changes were observed in man given the therapeutic dose of zopiclone (7.5 mg). The tumor producing dose of zopiclone represents 800 times and the no effect level 80 times the proposed human dose (0.125 mg/kg).
Zopiclone and its metabolic products were tested for mutagenic potential in the following assays:

<table>
<thead>
<tr>
<th>ASSAY</th>
<th>INDICATOR SPECIES OR ORGANISM</th>
<th>DOSES USED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ames’ test</td>
<td>Salmonella typhimurium (TA98, TA100, TA1535, TA1537 &amp; TA 1538) Escherichia coli (WP2 uvrA)</td>
<td>Up to 500 mcg/plate with an without rat liver microsome activating enzymes.</td>
</tr>
<tr>
<td>Ames’ test</td>
<td>Salmonella typhimurium (5 strains as above) Escherichia coli (WP2 uvrA)</td>
<td>Concentrated urine extracts from rats treated at 1, 10 and 100 mg/kg for 20 days.</td>
</tr>
<tr>
<td>Ames’ test</td>
<td>Salmonella typhimurium (5 strains as above)</td>
<td>Up to 5000 mcg/plate with liver microsomal enzymes from B6C3F1 mice.</td>
</tr>
<tr>
<td>Ames’ test</td>
<td>Salmonella typhimurium (5 strains as above) Escherichia coli (WP2 uvrA)</td>
<td>1) Urine samples from volunteers receiving 7.5, 10 or 15 mg with or without liver microsomal enzymes. 2) Two major metabolites, N-oxide and N-desmethyl derivatives: up to 1000 mcg/ plate.</td>
</tr>
<tr>
<td>In vitro and In vivo host mediated assay</td>
<td>Saccharomyces cerevisiae (D7)</td>
<td>In vitro: up to 1000 mcg/mL In vivo, in mice: 100 mg/kg p.o.</td>
</tr>
<tr>
<td>Gene forward mutation test</td>
<td>Chinese Hamster Ovary cells (CHO/HG PRT)</td>
<td>Up to 200 mcg/mL with or without metabolic activation.</td>
</tr>
<tr>
<td>In vitro mammalian cell test for clastogenicity.</td>
<td>Chinese Hamster Ovary cells (CHO/K1 line)</td>
<td>Up to 200 mcg/mL with or without metabolic activation.</td>
</tr>
<tr>
<td>DNA repair Assay (William’s test)</td>
<td>Primary cultures of rat hepatocytes</td>
<td>Up to $10^4$ M.</td>
</tr>
<tr>
<td>Dominant lethal test</td>
<td>Rats and mice</td>
<td>Up to 120 mg/kg/day p.o.</td>
</tr>
<tr>
<td>Micronucleus test</td>
<td>Mice</td>
<td>Up to 630 mg/kg/day p.o.</td>
</tr>
<tr>
<td>Sex-linked recessive lethal test</td>
<td>Drosophila melanogaster cells (CHO/HG PRT)</td>
<td>2% solution p.o. activation.</td>
</tr>
</tbody>
</table>

All tests were negative. Zopiclone was neither a mutagen nor a clastogen and did not give rise to mutagenic metabolites either in experimental animals or in man.
REPRODUCTION AND TERATOLOGY

1. Fertility and general reproductive performance

The effect of zopiclone was evaluated in three studies. First, treated male rats were mated with treated female rats, the oral doses of zopiclone being 0, 2, 12 and 120 mg/kg. The males were treated for 10 weeks prior to mating, the females for 2 weeks prior to mating, during pregnancy and throughout a 3-week lactation period. In two further experiments, treated males (120 mg/kg) were mated with untreated females and untreated males were mated with treated females (120 mg/kg). Both of the latter experimental conditions included a control group.

Rate of pregnancy, number of implantations, rate of resorption and number of live fetuses were similar in control and low and medium dose-treated rats. However, mortality of pups was significantly higher in the mid dose group than in the control group.

At the 120 mg/kg dose, regardless whether treated males were mated with treated or untreated females, only ~10% of the females became pregnant and even in these animals resorption was complete. When high dose-treated females were mated with untreated males, the rate of pregnancy was only slightly lower than in controls (83% vs 100%) and all pregnant females delivered live fetuses. Survival of fetuses, up to day 21 of lactation, was significantly lower than in controls.

In conclusion, a 120 mg/kg dose of zopiclone induces sterility in male animals, while in females it affects pregnancy rate only slightly. Up to 12 mg/kg, the drug does not affect fertility and reproductive functions.

2. Teratology - rats

The study was performed in groups of 20 rats each, given zopiclone orally at doses of 0, 5, 25 and 125 mg/kg from day 5 to day 15 of gestation. In rats treated with the high dose of zopiclone, the following changes were seen when compared to the controls: food intake and final body weight (day 20) were slightly but significantly lower, the rate of resorption was somewhat higher (9% vs 6%) and the mean weight of live fetuses slightly but significantly lower (3.5 g vs 3.7 g). One pup had a sternal malformation, and five pups from the same mother had asymmetrical sternebrae. Both anomalies occur in the strain used. In conclusion, zopiclone is not teratogenic in rats in doses up to 125 mg/kg.

3. Teratology - rabbits

The study was performed in groups of 16 rabbits each given zopiclone orally at doses of 0, 5, 25 and 125 mg/kg from day 6 to day 16 of gestation. Food intake and weight gain were significantly affected and in a dose-related manner. At the 125 mg/kg dose, the rabbits actually lost some weight by the end of treatment. The mean weight of live fetuses in this group was significantly lower than in the controls (31.5 g vs 35.8 g). Three of the fetuses
were malformed, 1/109 live fetuses in the mid dose and 2/129 live fetuses in the high dose, exhibiting malformations of the urinary tract, exencephaly and forelimbs with clubfeet and malformations of the large heart vessels, respectively. These malformations do occur in the strain used. In conclusion, zopiclone is not teratogenic in rabbits in doses up to 125 mg/kg.

4. Perinatal and postnatal study

This was a two generation study in which male and female offsprings (F1 generation) of treated mothers were bred and the F2 generation also observed.

Zopiclone was given orally at doses of 0, 10, 50 and 250 mg/kg from day 17 of gestation to day 28 of lactation. The following significant changes were observed: smaller litter size in the high dose group, lower body weights at birth and at weaning in the mid and high dose groups, dose-related increase of mortality at birth and between days 1 and 28. Mortality during lactation was significantly different from control even in the 10 mg/kg group. Cannibalization of pups increased in a dose-related manner; this effect might have been due to the fact that the pups were sedated, hypothermic and had problems with suckling.

Gross behaviour, physical development, auditory function, spontaneous motor activity and learning behaviour were normal in the surviving F1 pups. Males and females from the F1 generation mated successfully except for three rats which were infertile (one male rat from the 50 mg/kg group and one male and one female rat from the 250 mg/kg group). The male rat from the mid dose group had bilateral hypoplastic testes and epididymis. Mortality and weights of the F2 generation were within the normal range for the strain used. One F2 pup, from the mid dose group, had oligodactyly with syndactyly of the left forelimb.
REFERENCES


56) Trifiletti RR, Snyder SH. Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors. Mol Pharmacol 1984;26:458-69.


PART III: CONSUMER INFORMATION

Pr IMOVANE®
Zopiclone tablets

This leaflet is part III of a three-part "Product Monograph" published when IMOVANE was approved for sale in Canada and is designed specifically for Consumers. Please read this information before you start to take your medicine. Keep this leaflet until you have finished all your tablets, as you may need to read it again. This leaflet should not replace a discussion between you and your doctor about the risks and benefits of IMOVANE. This leaflet is a summary and will not tell you everything about IMOVANE. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
IMOVANE is a prescription medication intended to help you sleep if you have transient and short-term insomnia. Symptoms of insomnia may vary: you may have difficulty in falling asleep, or awaken often during the night, or awaken early in the morning, or you may have all three symptoms.

Treatment with IMOVANE should usually not go on for more than 7-10 days and should be restricted for insomnia where disturbed sleep results in impaired daytime functioning. IMOVANE does not treat the underlying cause of your insomnia.

What it does:
IMOVANE is one of several prescription sleeping pills that have generally similar properties such as a calming effect.

If you are prescribed sleep medications, you should consider both their benefits and risks. Important risks and limitations include the following:
• you may become dependent on the medication,
• the medication may affect your mental alertness or memory, particularly when not taken as prescribed.
(see Warnings and Precautions)

When it should not be used:
Do not use IMOVANE if you have:
• a muscular disease known as myasthenia gravis
• a severe hepatic insufficiency (liver problems)
• severe lung or respiratory disease, including sleep apnea.
• a known allergy to zopiclone or any of the ingredients IMOVANE contains (see What the nonmedicinal ingredients are).

What the medicinal ingredient is:
The active ingredient in IMOVANE is zopiclone.

What the nonmedicinal ingredients are:
The non-medical ingredients of IMOVANE 5 mg are corn starch, dicalcium phosphate, hydroxypropyl-methylcellulose, lactose, magnesium stearate, sodium carboxymethyl starch and titanium dioxide.

The non-medical ingredients of IMOVANE 7.5 mg are carnauba wax, croscarmellose sodium, calcium phosphate dihydrate dibasic, FD&C Blue #1, magnesium stearate, microcrystalline cellulose, Opadry II White and polyethylene glycol.

What dosage forms it comes in:
IMOVANE is available in 5 mg and 7.5 mg tablets for oral administration.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions
• Taking IMOVANE with opioid medicines can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.

Complex sleep-related behaviours
There have been reports of people getting out of bed while not fully awake after taking IMOVANE and doing activities that they did not know they were doing. The next morning, they did not remember doing those activities. This unusual behaviour is more likely to occur when IMOVANE is taken with alcohol or other drugs that can make you sleepy such as those for the treatment of depression or anxiety. The activities you may do in these situations can put you and people around you in danger. Reported activities included driving a car ("sleep-driving"), leaving the house, making and eating food, talking on the phone, etc.

Important:
1. Do not take more IMOVANE than prescribed.
2. Do not use for longer than recommended by your physician. Treatment should be as short as possible, because the risk of dependence increases with the duration of treatment.
3. Do not take IMOVANE if you drink alcohol.
4. Talk to your doctor if you have had episodes of sleepwalking in the past, or if there is a history of sleepwalking in your family.
5. Talk to your doctor if you have a condition that affects your sleep, such as Periodic Limb Movement Disorder (involuntary movement of limbs during sleep) or Restless Legs Syndrome (urge to move legs, usually accompanied by uncomfortable and unpleasant sensations, that begins or worsens during periods of inactivity, typically in the evening and night).
6. Talk to your doctor about all of your medicines, including over-the-counter medicines and herbal products. Your doctor will tell you if you can take IMOVANE with your other medicines.
7. You and people close to you should watch for the type of unusual behaviour described above. If you find out that you
have done *any* such activities for which you have no memory you should call your doctor immediately.

**Mental Alertness:**
IMOVAINE may affect your ability to be alert next day.
DO NOT DRIVE A CAR or operate potentially dangerous machinery:
- If you do not feel fully awake
- If it has not been at least 12 hours since taking the medicine, even if you feel fully awake, especially in elderly patients and in patients who take the 7.5 mg dose
- In all cases, until you experience how the drug affects you next day

**Memory problems:** IMOVAINE may cause a special type of memory loss (amnesia); you may not recall events that occurred during some period of time, usually several hours, after taking the drug. This lapse is usually not a problem, because the person taking the sleeping pill intends to be asleep during this critical period of time. But it can be a problem if you take the medication to induce sleep while travelling, such as during an airplane flight, because you may wake up before the effect of the drug is gone. This has been called “traveller’s amnesia”. DO NOT TAKE IMOVAINE when a full night's sleep is not possible before you would again need to be active and functional; e.g., an overnight flight of less than 8 hours. Memory lapses may occur in such situations. Your body needs time to eliminate the medication from your system.

**Tolerance/Withdrawal Symptoms:**
After nightly use, sleeping pills may lose some of their effectiveness and you may also develop a degree of dependence.

When taking IMOVAINE, you may get awakened during the last third of the night or feel anxious or nervous during the day. If this occurs, tell your doctor.

You may also experience “withdrawal effects” when you stop the medication after taking it for only a week or two. But usually, these withdrawal effects are more common and severe after long periods of continuous use. For instance, on the first few nights after stopping the medication, you may find that insomnia is worse than before taking the sleeping pills. This type of withdrawal symptom is known as “rebound insomnia”.

Other withdrawal effects following abrupt stopping of sleeping pills may range from unpleasant feelings to a major withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremor, and rarely, convulsions. The severe symptoms are uncommon. If you have been taking sleeping pills for a long time, discuss with your physician when and how it would be best for you to stop.

**Dependence/Abuse:**
All prescription sleeping pills can cause dependence (addiction) especially when used regularly for more than a few weeks, or at higher doses. Some people develop a need to continue taking these drugs, not only for continued therapeutic effect, but also to avoid withdrawal symptoms or to achieve non-therapeutic effects.

Individuals who depend, or have depended at any time in the past, on alcohol or other drugs may be at particular risk of becoming dependent on drugs of this class. But all people are at some risk.
Consider this matter before you take these medications beyond the recommended 7-10 days, because longer treatment times increase the risk of dependence. The risk of dependence is also greater in patients with a history of mental disorders and/or alcohol or drug abuse.

**Mental and Behavioural Changes:**
A variety of abnormal thinking and behavioural changes may occur when you use prescription sleeping pills. Some of these changes include aggressiveness and extroversion which seem out of character. Other changes, although rare, can be more unusual and extreme. These include confusion, strange behaviour, restlessness, agitation, irritability, nightmares, hallucinations, delusion (a false belief or wrong judgment, held with conviction despite evidence to the contrary), feeling like you are not yourself, and feeling more depressed, which may lead to suicidal thinking.

It is rarely clear whether such symptoms are caused by the medication, or by an illness that was present before the medication was used, or are simply spontaneous happenings. If you develop any unusual disturbing thoughts or behaviour while using IMOVAINE, discuss the matter immediately with your doctor.

**Worsening of Side Effects:**
DO NOT CONSUME ALCOHOL WHILE TAKING IMOVAINE. Some medicines may also worsen side effects that some patients experience with IMOVAINE (see Interactions with this medication).

**Elderly:** An increased risk of falls and fractures has been reported in elderly people who take sleeping pills such as IMOVAINE.

**Effects on Pregnancy:**
Certain sleeping pills have been linked to birth defects when taken during the early months of pregnancy. It is not yet known if IMOVAINE could cause similar effects. In addition, sleeping pills taken during the last weeks of pregnancy have been known to sedate the baby and may also cause withdrawal symptoms after birth. Therefore, DO NOT TAKE IMOVAINE at anytime during pregnancy, it may affect the developing baby.

**Use in Nursing Mothers:** IMOVAINE passes into breast milk. Therefore, if you are breast feeding, this medicine should be avoided. Your doctor will discuss this with you.

**BEFORE you use IMOVAINE talk to your doctor or pharmacist if:**
- You have a lung disease or breathing problems.
- You have liver or kidney condition.
- You have a mental disorder.
• You have a history of depression and/or suicide thoughts or attempts.
• You have had unexpected reactions to alcohol or sedative medications in the past, such as irritability, aggression, hallucinations, etc.
• You have a history of drug or alcohol abuse or addiction.
• You are planning to become pregnant, if you are pregnant, or if you become pregnant while taking this medication.
• You are breastfeeding.
• You consume alcohol.
• You are taking opioid medicines or other central nervous system depressants such as sedative or hypnotics (see INTERACTIONS WITH THIS MEDICATION), as well as if you are taking any other medicines, including over-the-counter medicines and herbal products.
• You have lactose intolerance.

INTERACTIONS WITH THIS MEDICATION

Do not use IMOVANE if you drink alcohol. Do not use IMOVANE along with other medications, over-the-counter medicines or herbal products without first discussing this with your doctor or pharmacist.

IMOVANE may produce more pronounced side effects when co-administered with:
• Alcohol
• Other tranquilizers or sleeping pills
• Sedative antihistamines
• Anticonvulsants (medicines used to control or prevent convulsions)
• Narcotic analgesics (opioids) (see Serious Warnings and Precautions box)
• Antipsychotics, antidepressants and other psychotropic medications (mood altering drugs) which themselves can make you sleepy.

Other drugs which may interact with IMOVANE by affecting the way the drug is metabolized by the enzyme CYP3A4 in the liver include:
• CYP3A4 inhibitors, such as erythromycin, clarithromycin, ketoconazole, itraconazole, and ritonavir;
• CYP3A4 inducers, such as rifampicin or rifampin, carbamazepine, phenobarbital, phenytoin, and St. John’s wort.

PROPER USE OF THIS MEDICATION

IMOVANE is an effective medication and is relatively free of serious problems when used for the short-term management of insomnia. Sleeplessness may last only for a short time and may respond to brief treatment. The risks and benefits of prolonged use should be discussed with your doctor.

Usual Adult dose:

IMOVANE should be taken at bedtime just before retiring for the night.

Adults: The recommended starting dose is 3.75 mg (one half of a 7.5 mg tablet). This can be increased to 5 mg or 7.5 mg if advised by your doctor.

Special population: Elderly (65 years of age or more), debilitated patients and/or patients with liver, kidney, or chronic respiratory problems should start with 3.75 mg (one-half of a 7.5 mg tablet) at bedtime just before retiring. The dose in elderly, debilitated patients and/or patients with liver or kidney problems is not to exceed 5 mg.

Follow your doctor’s advice about how to take IMOVANE, when to take it, and how long to take it. The lowest effective dose should be used.

Do not increase the prescribed dose of IMOVANE.

Do not take IMOVANE if it is not prescribed for you.

Treatment with IMOVANE should usually not exceed 7-10 consecutive days. Do not take IMOVANE for more than 7-10 days without first consulting your doctor. If you still have problems sleeping after you finish your tablets, contact your doctor again.

Do not take IMOVANE if you drink alcohol.

IMOVANE is not indicated for patients under 18 years of age. Do not take IMOVANE if you are under 18 years of age.

Do not drive a car or operate potentially dangerous machinery until you experience how this drug will affect you the next day (see WARNINGS AND PRECAUTIONS, Mental Alertness).

Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms. Show the doctor your bottle of tablets.

Missed Dose:

IMOVANE should be taken at bedtime just before retiring for the night. If you miss a dose, wait and take your next dose at your regular time. Do not take 2 doses at the same time. Do not make up for a missed dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Common Side Effects:
The most common adverse reaction seen with IMOVANE is taste alteration (bitter taste).
IMOVAINE may cause drowsiness, dizziness, lightheadedness, and difficulty with coordination. Users must be cautious about engaging in hazardous activities requiring complete mental alertness, e.g., operating machinery or driving a motor vehicle. This risk is increased by concomitant intake of alcohol.

How sleepy you are the day after you use IMOVAINE depends on your individual response and on how quickly your body gets rid of the medication. The larger the dose, the more likely that you will experience drowsiness, etc., the next day. It is important that you comply with the dose your physician has prescribed. If you experience excessive drowsiness the next day that affects your ability to perform tasks in the morning contact your physician as your dose may need to be reduced (see Warnings and Precautions, Mental Alertness).

Elderly patients are especially susceptible to side effects. Excessive drowsiness in the elderly may result in falls and fractures.

Do not drink alcohol while using IMOVAINE. Do not use sleeping pills along with other medications without first discussing this with your doctor.

Withdrawal-related side effects: You may experience an increase in sleep difficulties (rebound insomnia) and/or “increased daytime anxiety” (rebound anxiety) for one or two days after discontinuing IMOVAINE (see Warnings and Precautions, Tolerance/Withdrawal Symptoms).

Allergic reactions:
Rare cases of severe allergic reactions have been reported. Symptoms may include:
- swelling of the tongue or throat, trouble breathing, nausea and vomiting. Get emergency medical help if you get these symptoms after taking IMOVAINE.

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Seek urgent medical attention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe allergic reactions (swelling of the tongue or throat, trouble breathing, nausea and vomiting)</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td>Withdrawal effects (abdominal and muscle cramps, vomiting, sweating, tremor, and, very rare cases of convulsions)</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td>Rare</td>
<td>Somnambulism (sleepwalking) – getting out of bed while not fully awake and do activities you do not remember the day after</td>
<td>Only if severe</td>
</tr>
<tr>
<td>Very rare</td>
<td>thoughts of death or suicide</td>
<td>In all cases</td>
</tr>
<tr>
<td>Unknown</td>
<td>Trouble breathing</td>
<td>Only if severe</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking IMOVAINE, contact your doctor or pharmacist.

Reporting Side Effects
You can report any suspected side effects associated with the use of health products to Health Canada by:
- Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-healthproducts/medeffect-canada.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.
HOW TO STORE IT

Store in a dry place, at room temperature (15°C - 30°C). Protect from light. Do not exceed the expiry date indicated on the container.

Keep in a safe place out of reach and sight of children.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be obtained at: www.sanofi.ca or by contacting the sponsor, sanofi-aventis Canada Inc., at: 1-800-265-7927

This leaflet was prepared by sanofi-aventis Canada Inc.

Last revised: September 27, 2018